India amends drug trial compensation rules
This article was originally published in SRA
Executive Summary
India is making a series of much-awaited modifications to its clinical trial compensation regulations. Among other things, there are clarifications relating to injury or death due to an investigational product not having its intended therapeutic effect and to the requirement of free medical management for trial-related injuries1.